Compass Biotechnologies Inc. (COBI) Financials Nov 5, 2014, 8:10 p.m.
Income Statement Balance Sheet Cash Flow Statement
Annual Financials for Compass Biotechnologies Inc.
Fiscal year is February-January. All values USD millions. 2008 2009 2010 2011 2012 5-year trend
Sales/Revenue 0 0 0 0 0
Cost of Goods Sold (COGS) incl. D&A 165 547 621 78,074 60,718
COGS excluding D&A 0 0 0 0 0
Depreciation & Amortization Expense 165 547 621 78,074 60,718
Depreciation 165 547 621 - -
Amortization of Intangibles - - - 78,074 60,718
Gross Income (165) (547) (621) (78,074) (60,718)
2008 2009 2010 2011 2012 5-year trend
SG&A Expense 856,215 630,556 309,618 1.34M 835,238
Research & Development 530,016 272,889 87,479 105,050 79,477
Other SG&A 326,199 357,667 222,139 1.24M 755,761
Other Operating Expense 0 0 0 70,953 11,421
Unusual Expense 0 0 4,895 0 (6,000)
EBIT after Unusual Expense 0 0 (4,895) 0 6,000
Non Operating Income/Expense 0 0 70,025 0 25,235
Non-Operating Interest Income - - - - -
Equity in Affiliates (Pretax) 0 - - 0 0
Interest Expense 0 0 0 0 -
Gross Interest Expense 0 0 0 0 -
Interest Capitalized 0 0 0 0 0
Pretax Income (856,380) (631,103) (245,109) (1.49M) (876,142)
Income Tax 0 0 0 0 0
Income Tax - Current Domestic 0 0 0 0 0
Income Tax - Current Foreign 0 0 0 0 0
Income Tax - Deferred Domestic 0 0 0 0 0
Income Tax - Deferred Foreign 0 0 0 0 0
Income Tax Credits 0 0 0 0 0
Equity in Affiliates 0 0 0 0 0
Other After Tax Income (Expense) 0 0 0 0 0
Consolidated Net Income (856,380) (631,103) (245,109) (1.49M) (876,142)
Minority Interest Expense 0 0 0 0 0
Net Income (856,380) (631,103) (245,109) (1.49M) (876,142)
Extraordinaries & Discontinued Operations (62,669) 0 0 0 0
Extra Items & Gain/Loss Sale Of Assets (62,669) 0 0 0 0
Cumulative Effect - Accounting Chg 0 0 0 0 0
Discontinued Operations - - - 0 0
Net Income After Extraordinaries (919,049) (631,103) (245,109) (1.49M) (876,142)
Preferred Dividends 0 0 0 0 0
Net Income Available to Common (856,380) (631,103) (245,109) (1.49M) (876,142)
EPS (Basic) (0.80) (0.80) (0.12) (0.14) (0.03)
Basic Shares Outstanding 983,853 989,600 2.13M 10.62M 27.51M
EPS (Diluted) (0.80) (0.80) (0.12) (0.14) (0.03)
Diluted Shares Outstanding 983,853 989,600 2.13M 10.62M 27.51M
EBITDA (856,215) (630,556) (309,618) (1.41M) (846,659)
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
Income Statement Balance Sheet Cash Flow Statement
Annual Financials for Compass Biotechnologies Inc.
Fiscal year is February-January. All values USD millions. 2008 2009 2010 2011 2012 5-year trend
Sales/Revenue 0 0 0 0 0
Cost of Goods Sold (COGS) incl. D&A 165 547 621 78,074 60,718
COGS excluding D&A 0 0 0 0 0
Depreciation & Amortization Expense 165 547 621 78,074 60,718
Depreciation 165 547 621 - -
Amortization of Intangibles - - - 78,074 60,718
Gross Income (165) (547) (621) (78,074) (60,718)
2008 2009 2010 2011 2012 5-year trend
SG&A Expense 856,215 630,556 309,618 1.34M 835,238
Research & Development 530,016 272,889 87,479 105,050 79,477
Other SG&A 326,199 357,667 222,139 1.24M 755,761
Other Operating Expense 0 0 0 70,953 11,421
Unusual Expense 0 0 4,895 0 (6,000)
EBIT after Unusual Expense 0 0 (4,895) 0 6,000
Non Operating Income/Expense 0 0 70,025 0 25,235
Non-Operating Interest Income - - - - -
Equity in Affiliates (Pretax) 0 - - 0 0
Interest Expense 0 0 0 0 -
Gross Interest Expense 0 0 0 0 -
Interest Capitalized 0 0 0 0 0
Pretax Income (856,380) (631,103) (245,109) (1.49M) (876,142)
Income Tax 0 0 0 0 0
Income Tax - Current Domestic 0 0 0 0 0
Income Tax - Current Foreign 0 0 0 0 0
Income Tax - Deferred Domestic 0 0 0 0 0
Income Tax - Deferred Foreign 0 0 0 0 0
Income Tax Credits 0 0 0 0 0
Equity in Affiliates 0 0 0 0 0
Other After Tax Income (Expense) 0 0 0 0 0
Consolidated Net Income (856,380) (631,103) (245,109) (1.49M) (876,142)
Minority Interest Expense 0 0 0 0 0
Net Income (856,380) (631,103) (245,109) (1.49M) (876,142)
Extraordinaries & Discontinued Operations (62,669) 0 0 0 0
Extra Items & Gain/Loss Sale Of Assets (62,669) 0 0 0 0
Cumulative Effect - Accounting Chg 0 0 0 0 0
Discontinued Operations - - - 0 0
Net Income After Extraordinaries (919,049) (631,103) (245,109) (1.49M) (876,142)
Preferred Dividends 0 0 0 0 0
Net Income Available to Common (856,380) (631,103) (245,109) (1.49M) (876,142)
EPS (Basic) (0.80) (0.80) (0.12) (0.14) (0.03)
Basic Shares Outstanding 983,853 989,600 2.13M 10.62M 27.51M
EPS (Diluted) (0.80) (0.80) (0.12) (0.14) (0.03)
Diluted Shares Outstanding 983,853 989,600 2.13M 10.62M 27.51M
EBITDA (856,215) (630,556) (309,618) (1.41M) (846,659)
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
